Penester 5mg 30 tablets — Made in Czech — Free Delivery

Indications

• Prostate adenoma (in order to reduce the size of the enlarged gland, improve the outflow of urine and reduce the severity of symptoms);
• treatment of benign prostatic hyperplasia (BPH);
• to prevent urological interventions (due to its ability to reduce the risk of acute urinary retention) and surgical procedures, including transurethral resection of the prostate and prostatectomy.

Application

The recommended dose is 1 tablet of 5 mg 1 time per day, regardless of the meal. for patients with renal insufficiency of varying severity (with a decrease in creatinine clearance to 0.9 ml / min), as well as for elderly patients, dose adjustment is not required. there is evidence that the excretion of finasteride in patients aged 70 years is reduced.

The duration of treatment is determined by the doctor individually.

Contraindications

Hypersensitivity to finasteride or other components of the preparation.

Side effects

Immune system disorders: hypersensitivity reactions including itching, urticaria and swelling of the lips and face.

Mental disorders: decreased sexual desire.

Skin and subcutaneous tissue disorders: rash.

Disorders of the reproductive system and mammary glands: impotence, ejaculation disorders (decrease in ejaculate volume), mammary gland hypertrophy, pain in the mammary glands, testicular tenderness.

Laboratory results: decrease in the level of prostate-specific antigen (see SPECIAL INSTRUCTIONS).

special instructions

Patients with a large volume of residual urine and/or severely reduced urination require careful monitoring, as they are at particularly high risk of obstructive uropathy.

Effects on Prostate-Specific Antigen (PSA) and Prostate Cancer Diagnosis: So far, no clinical benefit has been found from taking finasteride in patients with prostate cancer.

Before starting therapy with finasteride and subsequently during therapy, it is recommended to regularly conduct a digital rectal examination of patients and other examinations that are performed for prostate cancer.

Serum PSA levels can also be used to diagnose prostate cancer. In general, if the PSA concentration exceeds ng/mL (Hybritech test), further testing should be done and a biopsy should be considered; if the PSA concentration is 4-10 ng / ml, additional examination is recommended. Often, PSA concentrations in men with and without prostate cancer can be similar. Thus, regardless of treatment with finasteride, the presence of prostate cancer in men with BPH and a PSA concentration within the normal range cannot be ruled out. A PSA concentration of 4 ng/mL does not exclude the presence of prostate cancer.

Serum concentration correlates with the age of the patient and the size of the prostate, and the size of the prostate depends on the age of the patient. When evaluating the results of laboratory determination of PSA concentrations, one should take into account the fact that PSA concentrations in patients who take finasteride are reduced. During the first month of treatment, a sharp decrease in PSA concentration can be observed in most patients; soon the PSA concentration stabilizes at a new level. The concentration after treatment is approximately 2 times less than that before treatment.

Thus, in order for the PSA concentration, which is measured in typical patients taking finasteride for 6 months, to correspond to the normal range of concentration in men who do not take finasteride, it should be increased by 2 times. Any sustained increase in PSA levels in patients taking finasteride should be carefully evaluated, given that Penester therapy may not be appropriate in such patients.

Finasteride does not cause a statistically significant decrease in the concentration of free PSA (the ratio of the concentration of free PSA to total PSA). The ratio of free PSA concentration to total PSA remains unchanged even during treatment with finasteride. If the free PSA concentration is used to diagnose prostate cancer, then this indicator does not need to be adjusted in any way.

The preparation contains lactose, so patients with rare congenital forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use this preparation.

Use during pregnancy and lactation

Women who are potentially pregnant or pregnant should avoid contact with crushed Penestera tablets or those that have lost integrity. Due to the ability of type II 5-α-reductase inhibitors to inhibit the conversion of testosterone to dihydrotestosterone, these preparations, including finasteride, may cause developmental disorders of the vulva in the male fetus.

Penestera tablets are coated and this prevents contact with the active ingredient, provided that the tablet is not crushed and has not lost its integrity.

Penester is not prescribed to women. It is not known about the penetration of finasteride into breast milk.

Children.

The preparation is not used in children.

The ability to influence the reaction rate when driving vehicles and working with other mechanisms. Does not affect.

Interactions

Any clinically significant interactions of finasteride with other preparations have not been identified. Obviously, finasteride does not have a statistically significant effect on the enzymatic system of preparation metabolism with the participation of cytochrome p450. in men, interactions with propranol, digoxin, glyburide, glibenclamide, warfarin, theophylline, antipyrine, and phenazone have been studied; no clinically significant interactions of finasteride with these preparations have been identified.

Other concomitant therapy

Although special preparation interaction studies have not been conducted, it is known about the use of finasteride simultaneously with ACE inhibitors, paracetamol, acetylsalicylic acid, α-, β-adrenergic blockers, calcium channel blockers, cardiac nitrates, diuretics, H2-histamine receptor antagonists, HMG-CoA inhibitors -reductase, NSAIDs, quinalones and benzodiazepines, while not a single clinically significant interaction with negative consequences has been identified.

Overdose

To date, no clinically significant cases of finasteride overdose have been reported. there are no special recommendations for the treatment of overdose.

Storage conditions

Does not require special storage conditions.